1. Organisation for Economic Cooperation and Development. Pensions at a Glance 2017: OECD and G20 Indicators. Paris, France: OECD Publishing; 2017.
6. Lee DW, Seong SJ. Korean national dementia plans: from 1st to 3rd. J Korean Med Assoc 2018;61:298-303.
8. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, et al. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res 2002;36:281-6.
9. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252-65.
10. Liu J, Hlavka J, Hillestad RJ, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA: RAND Corporation; 2017.
11. Hlavka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment. Santa Monica, CA: RAND Corporation; 2018.
12. Liu JL, Hlavka JP, Coulter DT, Baxi SM, Mattke S, Gidengil CA. Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA: RAND Corporation; 2019.
14. Baxi SM, Girosi F, Liu JL. Assessing the preparedness of the Australian health care system infrastructure for an Alzheimer's disease-modifying therapy. Santa Monica, CA: RAND Corporation; 2019.
17. Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan. Clinicoecon Outcomes Res 2017;10:13-28.
21. Health Insurance Review & Assessment Service. Healthcare Bigdata Hub [Internet]. Wonju, Korea: Health Insurance Review & Assessment Service; c2020 [cited 2021 Jan 30]. Available from:
http://opendata.hira.or.kr/.
22. Organisation for Economic Co-Operation and Development. Health care resources [Internet]. Paris, France: Organisation for Economic Co-operation and Development; 2018 [cited 2021 Jan 30]. Available from:
https://stats.oecd.org/index.aspx?queryid=30183.
25. Dominguez JC, De Guzman MF, Uy JG, Yu JM, Ligsay A, Kang S, et al. P4‐549: Plasma‐based biomarker MDS‐OAβ differentiates Alzheimer's disease from other etiologies. Alzheimers Dement 2019;15(7S Part 29):P1527-P1528.
27. Choi H. Present and future of Korean geriatrics. J Korean Geriatr Soc 2011;15:71-9.
28. Lam J, Hlavka J, Mattke S. O1‐11‐02: Estimated impact of diagnostic tools for primary care settings on demand for specialist visits for patients with prodromal Alzheimer's disease. Alzheimers Dement 2019;15(7S Part 4):P224-P225.
29. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020;324:772-81.